Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by subaru1ion Aug 04, 2023 2:08pm
112 Views
Post# 35573837

RE:RE:RE:RE:mdjbrown....nice find...a bit to add to what you brought...

RE:RE:RE:RE:mdjbrown....nice find...a bit to add to what you brought...LABS made mention one or two CC's back....at the opening of the CC, Epidiolex sales approx. $900 million annually.    Point is, independent if it's the NDA or ANDA, the ANDA calling out LABS FDA DMF, but how about the NDA (new drug application) that requires a new drug monograph from the FDA that we are waiting on....we have a minimum now of TWO drug candidates very close to commercialization.
We could get news of the drug monograph this month for the NDA....new type of anitibiotic?...new cancer drug?, etc, etc, etc,?  

We know of 2 now for sure and what did CEO Mr. Pidduck say to shareholders several times during the past several CC's:  He said, 'if only one of these are approved it will change the face of the company'.

Once the global pharmaceutical company name is released as the partner with LABS, that press release will HIT a much bigger target audience and draw a much larger crowd of investors into LABS.

It's like in the duck blind, you feel that 'click' on your finger...safety is off, lay low and wait until they come into you, pick your bird and squeeze the trigger.  Imho, the safety is off now with LABS. 
<< Previous
Bullboard Posts
Next >>